I ncreasing evidence of the benefits of noninvasive ventilatory support in a variety of pulmonary disorders has led to the relatively widespread use of hi-level positive pressure support and noninvasive nasal positive pressure ventilation (NPPV). Assessment of PaC0 2 is essential for evaluation of the adequacy of alveolar ventilation in this setting. PaC0 2 can be measured on samples obtained by arterial puncture or from an indwelling catheter in the radial artery. Repeated sampling of arterial blood remains so far the "gold standard" for estimating the adequacy of ventilatory support. However, arterial catheterization needs costly equipment, specially trained personnel, and in most cases the environment of an ICU.l There is also a low but measurable morbidity associated with arterial catheterization. 2 Noninvasive assessment ofPaC0 2 can be performed by measuring transcutaneous C0 2 (TcPco 2 ) or peak expired C0 2 . The latter, however, is a poor predictor of PaC0 2 . 3 A Also, accurate measurement of peak expired C0 2 cannot be achieved during nasal continuous positive airway pressure ventilation because of continuous flow through the mask. Transcutaneous measurement of carbon dioxide theoretically appears more appropriate for monitoring PaC0 2 . This measurement is based on the observation that C0 2 has a high tissue solubility and diffuses through the skin. It can be performed by two different types of sensors: the Severinghaus electrode5·6 and the Hewlett-Packard TcPco 2 device (Waltham, Mass), which uses an infrared transcutaneous capnometer. 1 Most capnometers use the Severinghaus electrode.
Available data as to the precision of TcPco 2 have given conflicting results. 3 · 7 -17 Therefore, the present study was designed to evaluate a new device for the measurement of TcPco 2 . We wanted to test for agreement with arterial values, detect any possible drift of TcPco 2 over time, and describe the response of TcPco 2 when initiating or interrupting NPPV in hypercapnic patients.
MATERIALS AND METHODS
The study protocol was approved by the Ethics Committee of the University Hospital of Geneva. Patients who had been admitted in the ICU and equipped with an indwelling arterial catheter were considered for the present study. To be included, they had to be in hemodynamically stable condition without vasopressor amine treatment other than low-dose dopamine (:50.2 mglmin) to avoid cutaneous hypoperfusion or vasoconstriction. Twenty-six patients were included (18 men, 8 women, aged 68±10 years). Diagnoses included respiratory failure in eight, monitoring after heart failure or myocardial infarction in eight, neurologic disorders in six, severe systemic hypertension in two, pulmonary hypertension in one, and sepsis in one. At the time of the protocol, systoli c BP was 128±24 mm Hg, diastolic pressure was 61±13 mm Hg, and mean BP was 83±15 mm Hg. Mean body weight was 74± 11 kg. Eight patients were under perfusion of low doses of dopamine .
Transcutaneous measurements of carbon dioxide (TcPco 2 ) were performed with a capnograph (Fastrac; Sensormedics Corp; Yorba Linda, Calif). The sensor uses a Stow-Severinghaus electrode. Briefly, it consists of a pH-sensitive glass electrode, a silver/silver chloride reference electrode, and a heater; the electrodes are bathed in an electrolyte solution, that is covered with a gas-permeable Teflon membrane. The collar of the sensor heats the skin to promote local vasodilatation. Warming the skin also softens the keratin layer, thereby making the physical barrier to diffusion more permeable. 4 · 18 C0 2 diffuses from the skin through the membrane; it reacts with water to form H 2 C0 3 , which in tum dissociates into H+ and HC0 3 -; the H+ production modifies the pH in the electrolyte solution. Changes in pH are related to TcPco 2 according to the Henderson-Hasselbach equation. The signal produced is the voltage difference between the pH electrode and the silver/silver chloride reference electrode.1 ·6·7 Values of TcPco 2 reported by the sensor reflect correction factors used by the sys tem software to compensate for both patient temperature and sensor temperature. 19 After introducing barometric pressure, the capnograph was calibrated before each measurement, using a two-point dry-gas calibration with 5% and 10% C0 2 . Calibration takes approximately 10 min and is recommended each time the capnograph has been turned off or after a 4-h period of use. The skin was cleansed with alcohol and dried. The sensor was then placed on the skin of the anterior abdomen using a double-sided adhesive ring and a contact gel: the membrane surface temperature was set at 43.5°C (Fig 1) . TcPco 2 was continuously recorded on a paper chart. Arterial blood gases were determined with a gas analyzer (ABL 520; Radiometer; Copenhagen, Denmark).
The study protocol consisted of three parts.
Correlation Between TcPco 2 and PaC0 2 at Steady State
Twenty-six pairs of measurements were recorded from 26 different subjects. Because PaC0 2 can vary substantially even in patients in apparently stable condition, 20 we ensured that mterial -.:::::: _· -...;;::
The capnograph (Fastrac) witl1 the sensor placed on the skin of the anterior abdomen.
samples were taken after stabilization of TcPco 2 values for at least 3 min. We also checked for the stability of these values aftetwards: 3 min after blood sampling, changes in TcPco 2 were minimal and ranged from 0 to 3 mm Hg (mean±SD: 1±1 mm Hg). For correlation studies, PaC0 2 values were compared with values of TcPco 2 at time of sampling.
Possible Drift of TcPco 2 During Continuous Recording
To detect any systematic drift of TcPco 2 values as compared with PaC0 2 , we continuously recorded TcPco 2 in five patients for 4 h. We did not exceed 4 h to avoid any risk of skin burning as a consequence of the temperature of the sensor. Arterial samples were taken at the beginning of the recordings, then every hour for 4 h.
Response of Transcutaneous Measurements to Induced Changes in PaC0 2
In six hypercapnic patients, we examined the response of TcPco 2 to a ventilatory event that was expected to induce a change in PaC0 2 . The event consisted in initiating NPPV in five patients and interrupting NPPV in one. During the procedure, TcPco 2 was recorded continuously. Arterial blood samples were drawn 3 and 1 min before the event, then 1, 3, 5, 7, 9, and 20 min aftetwards. Values of PaC0 2 were paired with the corresponding values of TcPco 2 at the time of arterial blood sampling. Values obtained 1 min before the event were considered as baseline. An exponential fit curve was computed for PaC0 2 and TcPco 2 curves of each patient. 21 The "90% response tim e" (t90'r) was then calculated for each curve (ie, the time at which PaC0 2 or TcPco 2 had reached 90% of the final equilibrated value). The mean difference between t 90 % for TcPco 2 and t 90 % for PaC0 2 was reported as an index of the TcPco 2 response time itself. Results are reported as mean value (range).
Statistical Analysis
PaC0 2 and TcPco 2 were correlated by linear regression, with calculation of Pearson's coefficient of correlation (r).
We also calculated the bias and the limits of agreement between the parameters as described by Bland and Altman. two methods are defined as follows: d±2s. Ninety-five pe r cent of th e values of (TcPco 2 -PaC0 2 ) are expected to be within the limits of agreement.
Exponential fits for curves of PaC0 2 and TcPco 2 in response to induced changes were computed using software (GraphPad "Prism" Software (1994); GraphPad Software; San Diego, Calif) . Figure 3 shows the d and limits of agreement between the TcPco 2 and PaC0 2 . The d was 0.75 mm Hg; SD of d was 2.6 mm Hg; limits of agreement were therefore as follows : -4.5 to +6 mm Hg. Eight of 26 patients were receiving low-dose dopamine (::::;0.2 mg/min) . In these cases, correlation between TcPco 2 and PaC0 2 was not altered and appeared as close as for the rest of the group (Fig 2) . In five patients with prolonged, continuous recording, the mean values for (TcPco 2 -PaC0 2 ) showed no significant difference at 0, 1, 2, 3, and 4 h (p=0.873). Therefore, no significant drift ofTcPco 2 could be detected over this period; maximal difference between TcPco 2 and PaC0 2 reached 6 mm Hg after 4 h (Fig 4) . Figure 5 shows simultaneous recordings of TcPco 2 and PaC0 2 in all six patients, while initiating or interrupting NPPV. TcPco 2 followed the same trend as PaC0 2 , with a few minutes of delay, as expected. In all six patients, the first changes in TcPco 2 were observed during the first 60s following the ventilatory event. In four patients, a new steady state for PaC0 2 was reached after starting or interrupting NPPV, and lasted for up to 20 min. We computed an exponential fit for PaC0 2 and TcPco 2 values, and calculated the t 90 % for each curve. The difference between t 90 % for PaC0 2 and TcPco 2 indicates the lag time of the latter over the former. This lag time averaged 5:±:3 min (range, 1 to 9 min). In two patients (cases 4 and 6), PaC0 2 did not become sufficiently stable after the start of NPPV and this precluded computation of an exponential fit with calculation of the lag time. However, it can be estimated from the graph on Figure 5 that the response time of TcPco 2 in case 6 did not lag over PaC0 2 by more than a few minutes. In case 4, tl1ere was an initial drop in TcPco 2 without concomitant change in PaC0 2 , for the first 5 min; then both graphs followed a similar trend.
DISCUSSION
We have shown that TcPco 2 values, measured with the capnograph (Fastrac), showed a good agreement with simultaneous arterial measurements of PaC0 2 , without significant drift after 4 h of continuous recording.
A review of published studies, as summarized in Table 1 , shows conflicting results regarding agreement between TcPco 2 and PaC0 2 . 3 · 7 -17 Five studies, however, gave excellent correlation, two of them 7 · 11 indicating Pearson's coefficient of correlation (r) equal to 0.97, and three others 8 · 16 · 17 reporting bias values 2 of 1.5 mm Hg with SDs 2 of 3.5 mm Hg. Thus, the results that we obtained in the present study are among the best reported so far, and they seem appropriate for clinical application.
By contrast, in some other studies, the limits of agreement are such that measurement of TcPco 2 would appear unfit for clinical purposes such as monitoring NPPV. In some cases, it seems to be related to a particular capnograph. 3 · 8 However, other factors such as calibration before all measurements, frequent change of membranes, allowing sufficient time for stabilization of TcPco 2 signals, and adequate cutaneous perfusion are important in ensuring sufficient precision of transcutaneous measurements. TcPco 2 measurements are reported to be adversely affected by cutaneous vasoconstriction due to low cardiac output or vasoconstricting agents, hypothermia, and elevated cutaneous vascular resistance due to hypovolemic or cardiogenic hypotension.l2 A cardiac index below 1.5 Umin can dramat- ically increase the (TcPco 2 -PaC0 2 ) gradient. 1 However, Palmisano and Severinghaus 16 did not find any significant effect of use of vasopressors on bias, limits of agreement, or regression slope. Similarly we found that low-dose dopamine did not alter measurement of TcPco 2 . Finally, it is interesting to note that the error of TcPco 2 is the same in fat and lean subjects, and is unrelated to body mass index. 3 ·10 A drawback of the method is the necessity to change the skin site after 4 h to avoid skin burningand to recalibrate the capnograph. One might consider decreasing the temperature to allow a longer time at the same site. However, temperatures of approximately 43°C are required to maintain adequate perfusion at the skin site: lower sensor temperatures have been associated with longer response times 23 and would not be desirable. The limit of 4 h at 43°C must be considered as a rule of safety, but other investigators have reported no skin burn after pe1iods of 6 to 8 h at sensor temperatures of 43 to 44°C_7.9, 24 .25 Furthermore, although we found no significant drift of TcPco 2 vs PaC0 2 over a 4-h period, one case did show a (PaC0 2 -TcPco 2 ) difference of 6 mm Hg after 4 h of continuous recording. Others have reported, over periods of 6 to 7 h, a drift of 0.1 to 0.8 mm Hglh.7.9,24,25
The aim of our study was to evaluate if a TcPco 2 capnograph that appears suitable for measurements under steady-state conditions would also be suitable for monitoring noninvasive, intermittent ventilation. \Ve found that when a ventilatory event was induced by initiating or interrupting NPPV in hypercapnic 772 patients, a change in TcPco 2 was detected within <60 s, and that the trend accurately reflected the change in PaC0 2 . Moreover, by 3 min, at least half of the amplitude of the change in PaC0 2 had been displayed by TcPco 2 recording. An estimation of the lag time averaged 5±3 min (range, 1 to 9 min).
Our results therefore suggest that the apparatus would appear suitable for monitoring NPPV, with some important limitations that the clinician must bear in mind: there is a distinct possibility of occasional errant TcPco 2 values: Figure 3 , for instance, shows two values overestimating PaC0 2 by 8 to 12 mm Hg; the high correlation depicted between TcPco 2 and PaC0 2 values was obtained after recalibration for each individual measurement-a 10-min procedure that may appear time-consuming in clinical practice. Furthermore, although TcPco 2 did accurately detect acute changes in PaC0 2 in five of six cases, case 4 ( Fig 5) showed an initial drop in TcPco 2 \Vithout any concomitant change in PaC0 2 . Substantial changes in TcPco 2 should probably be confirmed by arterial blood gas determination, once a new steady state is reached. Also, the slow response time, although inferior to 1 min in our study, prevents TcPco 2 from detecting short, transient changes in PaC0 2 that can be associated with brief apneas or hypopneas. This point has been well illustrated by Lanigan and coworkers, 8 with healthy subjects breathing a hypercapnic gas mixture that will induce almost instantaneous changes on PaC0 2 . The lag time of various TcPco 2 devices in these studies ranged from 31 to 56 s. 8 Recording TcPco 2 would appear therefore unsuitable for monitoring patients with obstructive sleep apnea, for exampl~.
In patients with NPPV, howeve r , the correction-of long-lasting p e riods of hypoventilation or hyperventilation, particularly during slee p, re presents a major goal. Recently, three groups of inve stigators have used TcPco 2 monitoring to estimate the mean level of PaC0 2 dming the night. Naughton and colleagues25 found that treatment of Cheynes-Stockes breathing with nasal continuous positive ai1way pressure increased mean nocturnal TcPco 2 , and decreased the number of apneas , unde rscoring the role of hypocapnia in the pathoge n e sis of periodic breathing. In a different setting, Pipe r and Sullivan 26 found that tre atment with nasal continuous positive airway pressure in patients with combined obstructive sleep apneas and hypoventilation resulte d in gradual decrease of mean nocturnal TcPco 2 . Finally, MeechamJones and coworkers 27 found that treatment with nocturnal nasal pressure suppmt significantly decreased mean TcPco 2 in selected patients with COPD, and that this change was associated with improve d daytime PaC0 2 .
Our results suggest that TcPco 2 monitoring may give more detailed information than just the computation of m e an nocturnal PaC0 2 as re ported by others. 25 -27 The responses that we observed after initiating or interrupting NPPV show that the method can identify ventilatory events, as far as they last > 1 min , and may permit us to undertake the necessmy adjustments in ventilatmy support. This might be particularly important in patients who receive combined NPPV and 0 2 supple m e ntation, in whom monitoring by pulse oximetry alone has limited value.
